IMPAX Laboratories, Inc. Receives FDA Approval For Generic Version Of Colestid(R)

HAYWARD, Calif.--(BUSINESS WIRE)--May 3, 2006--IMPAX Laboratories, Inc. (OTC: IPXL - News) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's Abbreviated New Drug Application (ANDA) for a generic version of Colestid® (Colestipol Hydrochloride for Oral Suspension USP) 5 g Packet and 5 g Scoopful. Pharmacia and Upjohn Company (Pfizer) markets the 5 g Packet and the 5 g Scoopful as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Total brand sales of unflavored Colestid in the U.S. were $7.5 million for the 12 months ended March 31, 2006, according to Wolters Kluwer Health. IMPAX's Global Pharmaceuticals division intends to begin marketing this product soon.